More information about ACLARIS THERAPEUTICS INC.

Aclaris Therapeutics, Inc. is a dermatologist-led biopharmaceutical company committed to identifying, developing and commercializing innovative therapies to address significant unmet needs in medical and aesthetic dermatology. The Company is focused on underserved market segments with no FDA-approved medications or where treatment gaps exist. ​ Headquartered in Malvern, Pennsylvania, Aclaris was founded in 2012. The Company is led by a team with approximately 250 years of combined experience in developing and commercializing dermatologic treatments. The team’s insight into the needs of dermatologists, their patients and the complex regulatory and drug development landscape enables Aclaris to identify early-stage drug candidates with the potential to meet those needs. Aclaris is advancing a drug portfolio of innovative therapies to treat skin and hair conditions that adversely impact how patients look, feel and live. ​ A-101 40% topical solution (A-101), an investigational drug, is a proprietary, high-concentration hydrogen peroxide formulation for the treatment of seborrheic keratosis (SK), a common skin condition that impacts more than 83 million people in the U.S. A New Drug Application (NDA) filing for A-101 was accepted by the FDA in May 2017, with a Prescription Drug User Fee Act (PDUFA) action date of December 24, 2017. Currently, there are no FDA-approved medications to treat SK, and existing treatment procedures are often painful or invasive and can have undesirable outcomes like scarring or dyspigmentation. A 45% topical solution of A-101 is also in clinical development for verruca vulgaris (common warts). ​ Additionally, Aclaris expanded its pipeline beyond A-101 with the acquisition of a portfolio of Janus Kinase (JAK) inhibitor compounds. The Company is developing several treatments for alopecia areata (autoimmune skin disease characterized by hair loss on the scalp and body), androgenetic alopecia (male/female pattern hair loss) and vitiligo (autoimmune disease in which the skin loses its pigment).